IMMUNEERING CORP - CLASS A

IMRXNASDAQ

🏆 #3487 by market capUS Equity

$462.65▲ $32.89 (+7.11%)

Simulated price

🔔

Track IMRX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.1%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$267M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

28.0%

Moderate

💵FCF Margin

—

⚖️P/S Ratio

534.4x

Expensive

Otter Score

Fair

No chart data available for IMRX.

Trading Snapshot

Day Range: $456.80 – $467.24
52-Week Range: $3.86 – $8.48
Volume: $2.81B
Avg Volume: $2.11B
Shares Outstanding: 64.7M
Next Earnings: Nov 18, 2026

Fundamentals Snapshot

Annual Revenue: $500,000
Last Q Revenue: $130,420
P/E Ratio: —
P/S Ratio: 534.4x
EPS (TTM): $-1.03
Dividend Yield: —
Dilution (1yr): +108.0%

Why Investors Own IMRX

✓High-growth profile — revenue up +18.7% YoY with expanding US Equity exposure.
✓Healthy economics — 37% gross margin and 11% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IMMUNEERING CORP - CLASS A

IMRX

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

50.1%▲ +12.5% YoY

Operating Income

−$59M▼ −7.3% YoY

Free Cash Flow

−$45M▼ −17.4% YoY

Shares Outstanding

64.6M▲ +108.0% YoY

Net Cash

$125M▲ +$93M YoY

StockOtter · stockotter.space

About IMMUNEERING CORP - CLASS A

Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

🦦